Good news! Dr. Tong Wang, CSO of Centec and Dr. Jiahong Zhao, CMO of Centec were awarded as Gusu Leading Talents

Categories:Company News
Author:
Origin:
Time of issue:2021-12-24
Views:0

(Summary description)Suzhou, China, December 23, 2021 - Dr. Tong Wang, CSO (Chief Scientific Officer) and Dr. Jiahong Zhao, CMO (Chief Medical Officer) of CGeneTech have been selected as the second batch of Gusu Leaders in Suzhou City for the year 2021.

Good news! Dr. Tong Wang, CSO of Centec and Dr. Jiahong Zhao, CMO of Centec were awarded as Gusu Leading Talents

(Summary description)Suzhou, China, December 23, 2021 - Dr. Tong Wang, CSO (Chief Scientific Officer) and Dr. Jiahong Zhao, CMO (Chief Medical Officer) of CGeneTech have been selected as the second batch of Gusu Leaders in Suzhou City for the year 2021.

Categories:Company News
Author:
Origin:
Time of issue:2021-12-24
Views:0

Suzhou, China, December 23, 2021 - Dr. Tong Wang, CSO (Chief Scientific Officer) and Dr. Jiahong Zhao, CMO (Chief Medical Officer) of CGeneTech have been selected as the second batch of Gusu Leaders in Suzhou City for the year 2021.

Dr. Tong Wang received his bachelor's degree in chemistry from Peking University and his PhD in chemistry from Syracuse University. Dr. Wang has more than 20 years of experience in full chain drug development and management in top pharmaceutical companies and research institutes in the US. Prior to joining CGeneTech, Dr. Wang worked at Schering-Plough and Translational Genomics Institute/Translational Drug Development, where he led nearly ten world-first small molecule drug development projects in the medical fields of cancer, immunology, ophthalmology and metabolism, and successfully advanced four new drug projects to the clinical stage.

Dr. Tong Wang, CSO (Chief Scientific Officer) of CGeneTech

Dr. Tong Wang has been awarded the Suzhou Park Innovation and Technology Leader A Class Talent, High-end Foreign Expert Introduction Program, and Senior Engineer, and has obtained nearly 20 invention patents and published more than 10 academic papers.

Dr. Jiahong Zhao is a medical doctor from Fudan University School of Medicine, with more than 20 years of professional and team management experience in drug clinical trials, 6 years of work experience as a hematologist in clinical internal medicine and teaching experience in medical school. Before joining CGeneTech, he worked as Vice President and CMO of a large CRO company, responsible for more than 600 clinical practical projects, presided over the clinical development of 3 new varieties of blood products successfully marketed, wrote 7 varieties of drug instructions selected by the State Pharmacopoeia Commission, which became the standard version of the blood products industry and used to date, participated in the State Drug Administration and CDE organization as an external expert As an external expert, he participated in the "7.22 data verification work" and the drafting and revision of many technical guidelines organized by the State Drug Administration and CDE.

Dr. Jiahong Zhao, CMO (Chief Medical Officer) of CGeneTech

Dr. Jiahong Zhao has been awarded more than ten honorary titles such as special professor of Jiangsu University and Zhejiang University of Traditional Chinese Medicine, external reviewer of CDE Professional Committee on Blood Products, special editorial board member and reviewer of Zhongnan Pharmacology, member of Professional Committee on Research and Evaluation of Traditional Chinese Medicine Injectables, reviewer of pharmaceutical projects of Ministry of Science and Technology of China, Shanghai Science and Technology Commission and Shanghai Health and Health Commission.

Previous: The two backbones of CGeneTech won new honors in the third Jinji Lake skill Invitational Competition

Next: CGeneTech丨Make innovative drugs for the people with the mentality of the long march of thousands of miles

Previous: The two backbones of CGeneTech won new honors in the third Jinji Lake skill Invitational Competition

Next: CGeneTech丨Make innovative drugs for the people with the mentality of the long march of thousands of miles

Shengshi Taike has been awarded the "Double Yellow Egg" of Jiangsu Province's innovation and entrepreneurship talents

Jiangxiang is near Xiaoman, with warm air and moving grasshoppers. Recently, the selection results of Jiangsu Province's "Double Innovation Plan" for 2024 have been officially announced. Shengshi Taike's talent team has won the "Double Yellow Egg" award: the core team led by Dr. Wang Tong, Chief Scientific Officer, has been successfully selected as the "Double Innovation Team" in Jiangsu Province in 2024, and is the only "Innovation Team" in the field of biomedicine in Suzhou; Dr. Zhao Jiahong, Chief Medical Officer, has been successfully selected as a "Double Innovation Talent" in Jiangsu Province in 2024. The "Double Innovation Plan" in Jiangsu Province mainly focuses on introducing and funding scarce talents in the "high-precision and cutting-edge" and "bottleneck" fields, supporting the development of new technologies in key areas, and is an important brand project for talent work in Jiangsu Province. This plan focuses on the key industries prioritized for development in Jiangsu Province, playing an important role in enhancing independent innovation capabilities, promoting industrial structure optimization and upgrading, and driving rapid economic development. Dr. Wang Tong was just awarded the title of "Double Innovation Talent" in Jiangsu Province last year, and this time he led the company's core team to win the honor of "Double Innovation Team" in Jiangsu Province, fully reflecting the continuous innovation ability of the company's talent team. Dr. Wang Tong, as the Chief Scientific Officer of Shengshi Taike, has over 20 years of experience in the full chain drug research and management of top pharmaceutical companies and research institutes in the United States. He is a strategic scientist who can break through key technologies, drive emerging disciplines, and promote the new drug industry. Since joining Shengshi Taike, I have been awarded the title of leading technology talent at all levels, bringing innovative thinking and advanced technological means to the company. I have integrated and formed a complete new drug development and industrialization platform, leading the company's R&D team to accelerate the development of the new drug product pipeline. One of the core product pipelines, the hypoglycemic drug sengliptin, has been launched for sale. Dr. Zhao Jiahong, a core member of the "Double Creation Team", was also awarded the honor of "Double Creation Talent" in Jiangsu Province this time. Dr. Zhao Jiahong, as the Chief Medical Officer of Shengshi Taike, has over 20 years of experience in drug clinical trials and team management, and is an external expert of CDE; Has rich practical experience in medical affairs and early drug development, clinical development strategies, and international multicenter clinical trials, and has led and participated in over 600 clinical projects; I also have some experience in post market re evaluation of drugs. Since joining Shengshi Taike, I have been fully responsible for the company's new drug clinical development strategy and pathway, as well as post market expansion research and other important tasks. Among the core members of the "Double Creation Team", Dr. Lu Qin graduated from Fudan University with a major in Medical Systems Biology and holds the associate senior professional title. She has achieved fruitful research results in the field of biology, published multiple high-quality papers, obtained nearly 10 authorized invention patents, led the company's biology team to complete multiple project research tasks, and won multiple honors such as leading the park. Dr. Ouyang Zhenwu graduated from the Organic Chemistry Department of the Chinese Academy of Sciences. He has demonstrated outstanding academic and professional achievements in the field of pharmaceutical chemistry. He has published six high-quality papers in internationally renowned chemical journals, demonstrating his profound skills in chemical synthesis and drug design. Since joining the company, Dr. Ouyang has repeatedly used "innovative synthesis methods" to simplify the synthesis route, which not only significantly improves the efficiency of new drug screening, but also saves costs for the company in new drug development. Shengshi Taike, composed of these innovative talent teams, is a biotechnology company in the commercial stage. The core team has decades of experience in the entire lifecycle of international drugs and is committed to the research and industrialization of high-quality and differentiated small molecule innovative drugs. The company has built a rich pipeline of innovative drugs covering hypoglycemic, anticancer, and autoimmune diseases through an integrated drug research and development technology platform and diversified business perspectives.

2025-05-22

Media Attention | Yu Qiang, an "unsmart" entrepreneur, and his new diabetes drug Sengliptin

Qiang Yu, the founder and CEO of CGeneTech, a doctor of chemistry from Peking University, founded a biotechnology company in the United States at the beginning of this century, and later returned to China to found CGeneTech and developed a new type 2 diabetes drug, a new generation of DPP-4 inhibitor senpaglitin, which has now been approved for marketing.

2025-04-16